Clinical trials offer new options for advanced bladder/urothelial cancers
August 17, 2018
Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other immunotherapies can be most beneficial to patients with this difficult-to-treat disease. At Providence Cancer Institute, four new studies of different immunotherapy approaches are now open to patients:
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)
Study purpose: to determine whether the combination of nivolumab (trade name Opdivo, an FDA-approved checkpoint inhibitor) and ipilimumab (trade name Yervoy, an immunotherapy approved for other cancers) is more effective than standard chemotherapy in treating patients with previously untreated inoperable or metastatic urothelial cancer.
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Study purpose: to determine the efficacy and safety of nivolumab versus placebo in participants who have undergone radical surgery for invasive urothelial cancer.
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Study purpose: to compare the survival, response rate, disease-control rate and other outcomes of study participants treated with enfortumab vedotin (EV) to participants treated with chemotherapy. Read more about EV, which was recently granted FDA breakthrough therapy designation for patients with locally advanced or metastatic urothelial cancer, in OncLive.
ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Study purpose: to determine how patients with locally advanced or metastatic urothelial carcinoma respond to treatment with rucaparib (trade name Rubraca), a targeted therapy classified as a PARP inhibitor.
Medical oncologist Brendan Curti, M.D., is the principal investigator on all four of these studies. Dr. Curti is the director of genitourinary oncology research at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center.
For more information about these studies, or to enroll a patient, please call our Clinical Research office at 503-215-2614.
See more studies
Providence Cancer Institute currently offers nine clinical trials focused on genitourinary cancers. See all genitourinary studies. New studies are added frequently. For a complete list of all current studies in all cancer types, please visit our website.